GRAIL (GRALV) Stock Analysis

What GRAIL does

GRAIL, LLC is a biotechnology firm dedicated to pioneering solutions for the early identification of cancer. The company offers Galleri, a multi-cancer early detection screening test designed for healthy individuals aged 50 and above who show no symptoms. Additionally, it provides DAC, a diagnostic assistance tool aimed at accelerating the diagnostic process for patients with a clinical suspicion of cancer. Beyond initial detection and diagnosis, GRAIL is also engaged in developing tests for minimal residual disease (MRD) and other post-treatment monitoring applications. Established in 2015, the company originally operated as PSC15, Inc. before rebranding as GRAIL, LLC in January 2016. Headquartered in Menlo Park, California, GRAIL, LLC functions as a subsidiary of Illumina, Inc.

Key metrics

ETFs linked to GRALV

Broad-market and Healthcare sector ETFs an investor holding GRAIL is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how GRALV fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for GRAIL?

GRAIL trades under the ticker GRALV on NASDAQ.

Which exchange is GRALV listed on?

GRALV is listed on NASDAQ.

What sector does GRAIL operate in?

GRAIL is classified in the Healthcare sector (Medical - Diagnostics & Research industry).

How can PortView help analyze GRALV in a portfolio?

PortView shows GRALV's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.